Literature DB >> 27010428

Identification of seco-clavilactone B as a small-molecule actin polymerization inhibitor.

So Miyazaki1, Yukiko Sasazawa1, Takuma Mogi1, Takehiro Suzuki2, Keisuke Yoshida1, Naoshi Dohmae2, Ken-Ichi Takao1, Siro Simizu1.   

Abstract

Phenotype-based chemical screening is an attractive strategy for the identification of bioactive compounds. We searched for a compound that induces cellular morphological change and identified a novel compound that we named seco-clavilactone B (Seco-CB). Treatment with Seco-CB decreased the ratio of filament actin (F-actin) to globular actin (G-actin). An in vitro actin polymerization assay revealed that Seco-CB inhibited actin polymerization directly. Further analysis demonstrated that the inhibitory effect of Seco-CB on actin polymerization was associated with Seco-CB binding to either Thr5 or Cys285 of actin. These data indicate that Seco-CB is a novel actin polymerization inhibitor.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  actin polymerization inhibitor; bioprobe; chemical biology; cytoskeleton; seco-clavilactone B

Mesh:

Substances:

Year:  2016        PMID: 27010428     DOI: 10.1002/1873-3468.12154

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  Dpy-19 like 3-mediated C-mannosylation and expression levels of RPE-spondin in human tumor cell lines.

Authors:  Shohei Morishita; Takehiro Suzuki; Yuki Niwa; Naoshi Dohmae; Siro Simizu
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

2.  Involvement of DPY19L3 in Myogenic Differentiation of C2C12 Myoblasts.

Authors:  Kento Mori; Hongkai Sun; Kazuki Miura; Siro Simizu
Journal:  Molecules       Date:  2021-09-19       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.